News & Events: ASCENION GmbH - A LifeScience company

Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a…

This year’s BioVaria Anniversary Edition will, for the first time, extend over two days and include the promising field of digital health. Top-tier…

LentiBOOST^TM, an innovative gene therapy adjuvant, has got the green light from the FDA for use in a Phase III clinical trial. The technology, which…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

We’d like to thank all our clients, colleagues and partners in technology transfer, research and industry for the enjoyable and productive…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

Most of you will have heard about the approval of BLINCYTO^® and VONVENDI – both drugs based in part on our partners’ intellectual property. These are…

As a long-term partner and supporter of BioFIT Ascenion cordially invites you to join the event. BioFIT is a premier partnering platform in Europe for…

Technology transfer professionals from all over Europe have the unique opportunity to visit one of the world's largest and most respected centres for…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

Marta Catarino, Director of TecMinho, Portugal, is the new president of the pan-European association for technology transfer (TT) professionals,…

Around 40 commercially attractive, licensable technologies that were presented at this year’s BioVaria are now available online – including videos of…